PEAK6’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.76M Sell
156,695
-1,767
-1% -$83.7K 0.01% 831
2025
Q4
$8.06M Buy
158,462
+11,916
+8% +$609K 0.02% 738
2025
Q3
$8.13M Buy
146,546
+44,976
+44% +$2.63M 0.01% 788
2025
Q2
$7.01M Sell
101,570
-155,213
-60% -$10.6M 0.01% 791
2025
Q1
$17.8M Buy
256,783
+101,657
+66% +$8.4M 0.04% 372
2024
Q4
$13.3M Buy
+155,126
New +$16.8M 0.03% 466

Other funds holding NVO

PEAK6's NVO Position: Q1 2026 in Review

PEAK6 reduced its Novo Nordisk (NVO) stake by 1.1% in Q1 2026, selling an estimated $83.7K and leaving 156,695 shares worth $5.76M. The position accounts for 0.01% of the portfolio, ranked #831.

PEAK6 first reported a position in NVO in Q4 2024 and has held it in 6 quarters since. The position peaked at $17.8M in Q1 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • PEAK6 held 156,695 shares of Novo Nordisk worth $5.76M as of Q1 2026.
  • PEAK6 sold 1,767 Novo Nordisk shares in Q1 2026, an estimated $83.7K.
  • Novo Nordisk made up 0.01% of PEAK6's portfolio in Q1 2026, its #831 holding.
  • PEAK6 first reported a position in Novo Nordisk in Q4 2024 and has held it in 6 quarters since.
  • PEAK6's Novo Nordisk position peaked at $17.8M in Q1 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.